We recommend identifying the BCR‐ABL transcript type in every CML patient at diagnosis along with the cytogenetic study, linking the detected transcript with the patient's clinical findings, possible resistance to first‐line TKI. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.